Short Interest Watching: Can Tracon Pharmaceuticals Incorporated (NASDAQ:TCON)’s Tomorrow be Different? The Stock Had Increase in Shorts

November 17, 2016 - By Winifred Garcia   ·   0 Comments

Short Interest Watching: Can Tracon Pharmaceuticals Incorporated (NASDAQ:TCON)’s Tomorrow be Different? The Stock Had Increase in Shorts

The stock of Tracon Pharmaceuticals Incorporated (NASDAQ:TCON) registered an increase of 0.92% in short interest. TCON’s total short interest was 87,700 shares in November as published by FINRA. Its up 0.92% from 86,900 shares, reported previously. With 14,700 shares average volume, it will take short sellers 6 days to cover their TCON’s short positions. The short interest to Tracon Pharmaceuticals Incorporated’s float is 1.32%. About 1,731 shares traded hands. TRACON Pharmaceuticals Inc (NASDAQ:TCON) has declined 8.60% since April 15, 2016 and is downtrending. It has underperformed by 13.23% the S&P500.

TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $102.25 million. The Firm is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases. It currently has negative earnings. The Company’s research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring).

TRACON Pharmaceuticals Inc (NASDAQ:TCON) Ratings Coverage

Out of 3 analysts covering Tracon Pharmaceuticals Inc (NASDAQ:TCON), 2 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. Tracon Pharmaceuticals Inc has been the topic of 3 analyst reports since July 29, 2015 according to StockzIntelligence Inc. The stock of TRACON Pharmaceuticals Inc (NASDAQ:TCON) has “Buy” rating given on Wednesday, July 29 by Roth Capital. The firm earned “Buy” rating on Wednesday, July 29 by TH Capital. The company was upgraded on Friday, September 4 by Zacks.

TCON Company Profile

TRACON Pharmaceuticals, Inc., incorporated on October 28, 2004, is a clinical-stage biopharmaceutical company. The Firm is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company’s research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring). The Company’s lead product candidate, TRC105, is an endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor (VEGF) pathway. TRC205 is being developed for the treatment of fibrotic disease. The Firm is also developing TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma.

More recent TRACON Pharmaceuticals Inc (NASDAQ:TCON) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on January 30, 2015. Also Quotes.Wsj.com published the news titled: “News TRACON Pharmaceuticals Inc.TCON” on January 24, 2015. 247Wallst.com‘s news article titled: “Tracon Pharmaceuticals Surges With Positive Study” with publication date: September 18, 2015 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Winifred Garcia


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>